HB10857: To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
- 1Introduced (current step)
- 2Passed One Chamber
- 3Passed Both Chambers
- 4Became Law
Here is how to read this bill
Start with the summary
It says what the bill does in plain language. The official text is one tab over.
Check where it is
The status badge says how far it has gotten. The History tab lists every step.
Follow it
We will email you when it moves. You need a free account.
Tell someone who votes on it
Email or call the sponsor, or find your own representatives, from the actions panel.
Bill information
Summary
To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Plain-language summary
This bill would change federal drug approval rules to speed up how new medicines and treatments are tested and developed. It amends two major health laws: the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. The bill affects pharmaceutical companies, drug developers, and the FDA (the agency that approves medicines). The bill is currently in the introduction stage, meaning it has just been proposed in Congress and has not yet been assigned to a for review.
AI-generated summary
What can I do?
It's early in the process — messages to the sponsor and your representatives carry the most weight right now.
Contact Your Representatives
Calling or emailing is the most direct way to weigh in — offices tally constituent contacts.
Find Your RepresentativesShare This Bill
Sharing helps others in your district get informed and involved.
HB10857: To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act…